Evidence map›Paper›PMID 42286649›Full record

ReviewMolecular cancer2026

Circular RNAs in tumor biology and immunology: molecular mechanisms and therapeutic implications.

Zhenyan Jiang, Yong Peng, Xiaojuan Yang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zhenyan JiangCenter for Molecular Oncology, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Yong PengCenter for Molecular Oncology, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China. yongpeng@scu.edu.cn.
Xiaojuan YangCenter for Molecular Oncology, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China. yangxiaojuan@wchscu.edu.cn.

Funding

National Natural Science Foundation of China 82273168West China Hospital, Sichuan University ZYGD23027
6 · The paper itself

Abstract

Cancer immunotherapy has revolutionized oncology, yet its efficacy remains frequently constrained by the immunosuppressive tumor microenvironment (TME). Circular RNAs (circRNAs) are covalently closed RNA molecules generated through back-splicing. Their lack of free ends confers strong resistance to exonuclease degradation and high molecular stability. Within tumor cells, circRNAs govern multiple cancer hallmarks via diverse regulatory mechanisms. Beyond these cell-intrinsic functions, circRNAs can be secreted as intercellular messengers that enter and reshape the TME by modulating antitumor immunity. Clinically, the high stability of circRNAs in body fluids highlights their potential as non-invasive liquid biopsy biomarkers for cancer diagnosis and prognosis. Furthermore, beyond targeting endogenous circRNAs, engineered circRNAs encoding tumor antigens or immunomodulatory proteins represent a promising platform for cancer immunotherapy. In this article, we briefly summarize recent advances in the understanding of circRNAs in tumor biology and immunology.

Indexed as

NeoplasmsRNA, CircularAnimalsBiomarkers, TumorGene Expression Regulation, NeoplasticHumansImmunotherapyTumor MicroenvironmentBiomarkers, TumorRNA, CircularCancer immunotherapyCircular RNATumor immunologyTumor microenvironment

Identifiers

PMID42286649
PMCPMC13682049

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.